Needham & Company LLC Reiterates Buy Rating for Artiva Biotherapeutics (NASDAQ:ARTV)

Artiva Biotherapeutics (NASDAQ:ARTV)‘s stock had its “buy” rating reiterated by research analysts at Needham & Company LLC in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $23.00 target price on the stock. Needham & Company LLC’s price target would suggest a potential upside of 118.84% from the company’s current price.

Several other analysts have also recently issued reports on the stock. TD Cowen initiated coverage on shares of Artiva Biotherapeutics in a research note on Tuesday, August 13th. They set a “buy” rating for the company. Cantor Fitzgerald started coverage on Artiva Biotherapeutics in a research report on Tuesday, August 13th. They issued an “overweight” rating and a $23.00 price target for the company. Wedbush reiterated an “outperform” rating and set a $18.00 price objective on shares of Artiva Biotherapeutics in a research report on Friday, August 30th. Finally, Jefferies Financial Group initiated coverage on Artiva Biotherapeutics in a report on Tuesday, August 13th. They issued a “buy” rating and a $21.00 target price for the company. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $21.25.

Artiva Biotherapeutics Trading Down 10.2 %

NASDAQ ARTV opened at $10.51 on Wednesday. The firm has a 50 day moving average price of $12.60. Artiva Biotherapeutics has a 1-year low of $9.68 and a 1-year high of $17.31.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.92) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.24). On average, research analysts predict that Artiva Biotherapeutics will post -4.6 earnings per share for the current fiscal year.

Institutional Trading of Artiva Biotherapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in ARTV. Acuta Capital Partners LLC purchased a new position in Artiva Biotherapeutics in the third quarter worth approximately $680,000. Charles Schwab Investment Management Inc. acquired a new position in shares of Artiva Biotherapeutics in the 3rd quarter valued at $623,000. MetLife Investment Management LLC acquired a new position in shares of Artiva Biotherapeutics in the 3rd quarter valued at $135,000. Finally, BNP Paribas Financial Markets purchased a new position in shares of Artiva Biotherapeutics during the 3rd quarter worth $42,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.